Summary
This in silico study examines the potential of Chinese bittersweet alkaloid I — a phytochemical compound — as an inhibitor of glycogen synthase kinase-3 beta (GSK-3β), an enzyme implicated in several diseases including type 2 diabetes and neurodegeneration. Using molecular docking, DFT calculations, NCI analysis, and ADME assessment, the authors characterise the compound's likely binding mode, electronic structure, and pharmacokinetic suitability. The findings are inferential and computational in nature, providing a theoretical basis for further experimental validation rather than clinical or laboratory confirmation.
UK applicability
This computational study has no direct UK farming or food systems relevance, but may inform future phytochemical research into plant-derived bioactive compounds with therapeutic potential, which could intersect with UK interests in medicinal plant cultivation or nutraceutical development.
Key measures
Binding affinity scores (kcal/mol); DFT-derived electronic properties; ADME pharmacokinetic parameters; non-covalent interaction indices
Outcomes reported
The study investigated the binding interactions and inhibitory potential of Chinese bittersweet alkaloid I against the enzyme GSK-3β using computational methods including molecular docking, density functional theory (DFT), non-covalent interaction (NCI) analysis, and ADME profiling.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.